9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
January 2023 in “International Journal of Clinical and Medical Education Research” Correct testosterone levels for age to treat prostate cancer, using low dose treatments as necessary.
21 citations
,
March 2013 in “Cancer Epidemiology, Biomarkers & Prevention” Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.
February 2012 in “Expert Review of Endocrinology & Metabolism” The document suggests more research is needed to understand the link between baldness and prostate cancer.
71 citations
,
September 2007 in “Cancer” Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.
17 citations
,
January 2016 in “American Journal of Epidemiology” Men with male pattern baldness have a higher risk of dying from prostate cancer.
14 citations
,
December 1998 in “The Journal of Clinical Endocrinology and Metabolism” MENT could be a better option than testosterone for male hormone therapy and birth control because it works well at lower doses and has fewer side effects on the prostate.
9 citations
,
January 2014 in “Medical Hypotheses” Higher DHT in male baldness may protect against prostate cancer.
4 citations
,
March 2018 in “PloS one” Men with less sun-sensitive skin have lower PSA levels, while men with more sun-sensitive skin have higher PSA levels.
4 citations
,
October 2002 in “BJUI” Finasteride treats hair loss but may affect prostate cancer detection.
3 citations
,
December 2016 in “Canadian Urological Association journal” Men with more advanced male pattern baldness have a higher risk of prostate cancer and more severe disease.
January 2024 in “Wiadomości Lekarskie” The ABI1 gene contributes to prostate cancer progression and treatment resistance.
Higher cholesterol levels increase aggressive prostate cancer risk.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
72 citations
,
January 2003 in “American Journal of Pathology” A protein called CBP is found in prostate cancer and can increase the effectiveness of certain prostate cancer treatments.
12 citations
,
March 2013 in “Cancer Causes & Control” Early balding, especially frontal, increases prostate cancer risk; more research needed.
8 citations
,
June 2016 in “Clinical Chemistry” PSA levels could help detect illegal steroid use in female athletes but face challenges like cost and PCOS prevalence.
6 citations
,
May 2008 in “Current Opinion in Oncology” 2007 research improved understanding of prostate cancer risk, diagnosis, and treatment, but also showed the need for personalized treatment and further study on certain therapies' risks.
3 citations
,
March 2018 in “BMC Cancer” Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.
1 citations
,
May 2023 in “Jurnal Kedokteran Diponegoro” Chemotherapy for prostate, bladder, and testicular cancer patients commonly causes hair loss, fatigue, and decreased appetite.
1 citations
,
August 2013 in “Journal of the National Cancer Institute” Early hair loss may increase the risk of prostate cancer, especially in African American men and those with frontal baldness.
June 2023 in “SPIRE - Sciences Po Institutional REpository” Extracellular vesicles and androgen receptors may help identify prostate cancer resistance and reduce SARS-CoV-2 infection.
August 2008 in “Current Opinion in Internal Medicine” In 2007, prostate cancer research improved understanding of risk, diagnosis, and treatment, but also showed heart risks with certain therapies and the need for personalized care.
January 2008 in “The Year book of endocrinology” Gene variant linked to prostate cancer, hormone levels, and hair loss.
76 citations
,
April 2005 in “Cancer Epidemiology, Biomarkers & Prevention” E211 G>A gene linked to lower risk of severe prostate cancer and hair loss.
October 2018 in “Journal of the European Academy of Dermatology and Venereology”
37 citations
,
April 2008 in “The Cochrane library” 5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.
22 citations
,
August 2014 in “Clinical endocrinology” Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.
2 citations
,
December 2006 in “Lancet Oncology” Finasteride significantly reduces PSA levels in men, and doctors should adjust PSA readings for those taking the drug.
35 citations
,
January 2012 in “The Journal of Sexual Medicine” Androgen Deprivation Therapy for prostate cancer often reduces sexual function but intermittent therapy may be more tolerable.